"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03404063","Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)",,"Completed","No Results Available","Myocardial Infarction","Drug: Cardiac Drug|Drug: Placebos","Reduction of infarct size|Infarct size reduction|Myocardial perfusion improvement|Increase of left ventricle ejection fraction (LVEF)|Left ventricle ejection fraction (LVEF) change against baseline.|Left ventricle end-systolic volume (ESV) change against baseline.|Left ventricle end-diastolic volume (EDV) change against baseline.|The occurrence of major adverse cardiovascular events|Quality of life improvement","John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CardioCell evaluation in AMI","October 20, 2017","July 2, 2020","March 31, 2021","January 19, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|Central Clinical Hospital of the MSWiA in Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03404063"
2,"NCT03418233","Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)",,"Completed","No Results Available","Heart Failure","Drug: CardioCell|Drug: Placebos","Left ventricle ejection fraction (LVEF) increase|An increase the result of 6 minute walk test|Myocardial perfusion improvement|An improvement the result of spiroergometric test|Left ventricle ejection fraction (LVEF) change against baseline|Left ventricle end-systolic volume (ESV) change against baseline|Left ventricle end-diastolic volume (EDV) change against baseline|NT pro-BNP level|The occurrence of major adverse cardiovascular events|Quality of life improvement","John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CardioCell in CIHF","April 19, 2018","January 27, 2021","March 31, 2021","February 1, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|The University Hospital in Cracow, Cracovia, Poland|Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego, Katowice, Poland|Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Katowice, Poland|Central Clinical Hospital of the MSWiA in Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03418233"
3,"NCT03423732","Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)",,"Active, not recruiting","No Results Available","Critical Limb Ischemia","Drug: CardioCell|Drug: Placebos","Change in pain-free walking distance|Amputation-free survival period|Ulcer-free survival|Ulcer-extension free survival|Change in tissue oxygen/CO2 tension|An improvement of tissue perfusion|Change in transcutaneous pressure of O2|Change in ABI score|Quality of life improvement, assessed by SF-36 questionnaire","John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CardioCell in N-O CLI","April 19, 2018","May 31, 2021","September 30, 2021","February 6, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Katowice, Poland",,"https://ClinicalTrials.gov/show/NCT03423732"
